3[1]Sheiner L B, Rosenberg B, Marathe V V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data [J]. J Pharmacokinet Biopharm,1977,5(5):445-479.
4[2]Sheiner L B. The population approach to pharmacoki-netic data analysis: rationale and standard data analysis methods [J]. Drug Metab Rev, 1984,15(2):153-171.
5[3]Beal S L. Population pharmacokinetic data and parameter estimation based on their first two statistical moments [J]. Drug Metab Rev, 1984,15(2):173-193.
6[4]Wang J, Liang W Q, Wu J J, et al. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method [J]. Acta Pharmacol Sin,2000,21(10):954-960.
7[5]Grasela T H, Sheiner L B, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data [J]. Clin Pharmacokinet, 1983,8(4):355-364.
8[6]Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Part Ⅱ. Phenytoin, carbamazeping, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate [J]. Clin Pharmacokinet, 1995,29(5):341-369.
9[7]LU Ming, ZHOU Huai-wu, SONG Ji-fen(吕明,周怀梧,宋继芬). Population kinetic program for Michaelis-Menten elimination [J]. Acta Pharmacologica Sinica(中国药理学报), 1990,11(1):85-88.(in Chinese)
10[8]RUI Jian-zhong, CAI Ming-hong, CHU Xiao-man, et al(芮建中,蔡明虹,储小曼,等). Nonmem approach for estimating population pharmacokinetic parameters of phentoin in Chinese epileptics [J]. Acta Pharmaceutica Sinica(药学学报), 1995,30(3):172-178.(in Chinese)
